Tags

Type your tag names separated by a space and hit enter

Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Contraception. 1990 Dec; 42(6):611-9.C

Abstract

This study evaluates the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome (PCOS). During the administration of the pill a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase of the Sex Hormone Binding Globulin (SHBG). The progressive decrease of the total androgenic activity explains the clinical results that have been obtained: at the 36th cycle of therapy acne disappeared in 100% of the cases, seborrea in 76.4% and hirsutism in 75%. Our results underline the need for a continuous administration without interruption of the pill with CPA in patients with clinical hyperandrogenic symptoms.

Authors+Show Affiliations

Falsetti L
Department of Obstetrics and Gynecology, University of Brescia, Italy.
Galbignani E
No affiliation info available

MeSH

Acne VulgarisAdultAlanine TransaminaseAlkaline PhosphataseAnalysis of VarianceAndrogen AntagonistsAndrostenedioneAspartate AminotransferasesBilirubinBlood GlucoseCholesterolContraceptives, Oral, CombinedCyproteroneCyproterone AcetateDehydroepiandrosteroneDermatitis, SeborrheicDrug CombinationsEthinyl EstradiolFemaleFollicle Stimulating HormoneHirsutismHumansLiverLuteinizing HormoneOvaryPolycystic Ovary SyndromeProlactinSex Hormone-Binding GlobulinTestosteroneTriglycerides

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2150631

Citation

Falsetti, L, and E Galbignani. "Long-term Treatment With the Combination Ethinylestradiol and Cyproterone Acetate in Polycystic Ovary Syndrome." Contraception, vol. 42, no. 6, 1990, pp. 611-9.
Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1990;42(6):611-9.
Falsetti, L., & Galbignani, E. (1990). Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception, 42(6), 611-9.
Falsetti L, Galbignani E. Long-term Treatment With the Combination Ethinylestradiol and Cyproterone Acetate in Polycystic Ovary Syndrome. Contraception. 1990;42(6):611-9. PubMed PMID: 2150631.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. AU - Falsetti,L, AU - Galbignani,E, PY - 1990/12/1/pubmed PY - 1990/12/1/medline PY - 1990/12/1/entrez KW - Acne KW - Biology KW - Contraception KW - Contraceptive Agents, Estrogen--administraction and dosage KW - Contraceptive Agents, Female--administraction and dosage KW - Contraceptive Agents--administraction and dosage KW - Contraceptive Methods--administraction and dosage KW - Cyproterone Acetate--administraction and dosage KW - Dermatitis KW - Developed Countries KW - Diseases KW - Endocrine Effects KW - Endocrine System KW - Ethinyl Estradiol--administraction and dosage KW - Europe KW - Family Planning KW - Follicle Stimulating Hormone--analysis KW - Genitalia KW - Genitalia, Female KW - Gonadotropins KW - Gonadotropins, Pituitary KW - Hirsutism KW - Hormone Antagonists KW - Hormones KW - Italy KW - Lipid Metabolic Effects KW - Lipids KW - Luteinizing Hormone--analysis KW - Mediterranean Countries KW - Oral Contraceptives, Combined--administraction and dosage KW - Oral Contraceptives--administraction and dosage KW - Ovarian Effects KW - Ovary KW - Physiology KW - Signs And Symptoms KW - Southern Europe KW - Treatment KW - Urogenital System SP - 611 EP - 9 JF - Contraception JO - Contraception VL - 42 IS - 6 N2 - This study evaluates the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome (PCOS). During the administration of the pill a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase of the Sex Hormone Binding Globulin (SHBG). The progressive decrease of the total androgenic activity explains the clinical results that have been obtained: at the 36th cycle of therapy acne disappeared in 100% of the cases, seborrea in 76.4% and hirsutism in 75%. Our results underline the need for a continuous administration without interruption of the pill with CPA in patients with clinical hyperandrogenic symptoms. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/2150631/Long_term_treatment_with_the_combination_ethinylestradiol_and_cyproterone_acetate_in_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -